Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma ...Middle East

MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology.

Hence then, the article about phase two cd19 antibody drug conjugate trial demonstrates promise for aggressive lymphoma was published today ( Friday 23/07/2021 - 05:30 PM ) and is available on ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma )

Also on site :

• ‘Harry Potter’ Series Star Paapa Essiedu Says He’s Received Death Threats Over Snape Casting: ‘I’ve Been Told, “Quit or I’ll Murder You”’
• Dozens injured after missile strike in Southern Israel
• Door Cam Catches Healthcare Worker After 7-Hour Shift—Footage Says It All